Drug news
FDA requires longer term trials for HyQvia (Halozyme/Baxter) for Primary Immonodeficiency
The FDA wants additional safety data before it will complete its review of the biologics license application (BLA) for HyQvia, a combination of immune globulin infusion and recombinant human hyaluronidase (rHuPH20) from Halozyme and Baxter under investigation to treat primary immunodeficiency disorder.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.